IRVINE, Calif.--Reprogen, a privately held functional genomics company here with a focus on reproductive medicine, announced the second closing of $1.4 million in a private financing round. The company announced the first closing of this round in February at $5.1 million. New participants included a Munich-based venture capital fund, Life Science Ventures, and Hambrecht and Quist. Reprogen CEO Jeffrey Miller said the financing provides a foundation for Reprogen to continue to enhance its three proprietary technologies. "These platforms enable us to efficiently identify and characterize novel drug targets involved in reproductive diseases," Miller said.
Miller credits Reprogen's new chief financial officer and vice-president of finance and administration, Sharon Tetlow, with bringing high-quality investors to its second closing. Tetlow, formerly of Terrapin Technologies, Synergen, Genentech, and Eli Lilly, brings 12 years' pharmaceutical and biotech experience to Reprogen. She holds an MBA from Stanford University.